EpiPaws

What EpiPaws does

EpiPaws, Inc. is a private, early-stage direct-to-consumer pet health company headquartered in Fort Lauderdale, Florida, that applies epigenetic DNA methylation analysis to companion animals. The company was founded by Andria Beal, PhD, whose prior PhD research produced the first age-estimation test for dolphins using molecular clocks, and who adapted that methodology to dogs and cats. EpiPaws sells two core product lines through its epipaws.com storefront: a one-time Pet Age Test priced at $120 that estimates chronological age from a cheek-swab sample (advertised accuracy within 12 months for most samples, with 75% of validation samples within 5 months), and a HealthScore biological-wellness test priced at $250 (or $189–$199 on subscription) that produces a biological health score, disease-risk association, and pet-specific recommendations. All samples are self-collected at home via cheek swab, mailed to the company's lab, and results are delivered through a web-based customer portal.

The company serves individual pet parents — primarily rescue and shelter adopters seeking accurate age for pets with unknown birthdays, and proactive pet-health consumers seeking ongoing longevity monitoring. A secondary customer segment comprises academic researchers, veterinary clinics, and rescue organizations that access the platform through research collaborations (e.g., a 100-cat feline-aging study with The Cat Health Company) and partnerships such as the Healthy Pet Connect telemonitoring integration with Fit Pets for Rescues. Marketing is conducted exclusively through the company's own e-commerce site, science-education content, email, and a citizen-science sample-contribution program; no third-party retail, distributor, or field-sales channels are indicated.

EpiPaws operates with 1–10 employees, is privately held, and has received undisclosed early-stage investment from FAU Tech Runway (2023-02-21) and New World Angels' Innovation Fund-I (2025-07-22). No revenue figure has been publicly disclosed. The company's commercial model rests on its proprietary epigenetic methodology, founder scientific credibility, and a growing pet methylation dataset, with subscription economics intended to convert one-time diagnostics into recurring longevity tracking.

Name

EpiPaws

Legal name

EpiPaws, Inc.

Website

https://epipaws.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

EpiPaws is a private direct-to-consumer pet health company that sells cheek-swab epigenetic DNA methylation tests for dogs and cats, estimating biological age, generating health scores, and identifying disease risk for individual pet owners and veterinary partners.

Ownership category

akta.pro rank

Product category

Pet Epigenetic Health Testing

NAICS

Pet and Pet Supplies Retailers (45991), Veterinary Services (54194)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular & Genetic Testing (Breed, Hereditary Disease, Oncology) (HLAMADAE)

akta.pro secondary industries

Epigenomics & Chromatin Profiling Services (HLAGANAF), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Epigenetic pet testing
• Pet age estimation
• Canine wellness screening
• Feline biological age
• Pet health diagnostics

Headquarters

HQ city

Fort Lauderdale

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales

Revenue model

1. Direct-to-Consumer Pet Age Testing Kits: One-time purchase of pet age estimation tests (Dog Age Test, Cat Age Test) priced at $120 per kit. Customers order via the EpiPaws website and receive a cheek swab kit by mail.
2. HealthScore Wellness Screening Kits: One-time or subscription-based biological health screening tests. Single purchase at $250; subscription plans at $199/6 months (Semi-Annual Plan) or $189/3 months (Quarterly Plan). Includes ongoing monitoring and portal access.
3. B2B / R&D Partnerships: EpiPaws offers epigenetic testing services to research institutions, veterinary clinics, and industry collaborators for clinical trials and research studies. The company invites partnerships for R&D collaborations on the science page.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

EpiPaws sells direct-to-consumer epigenetic test kits for dogs and cats that analyze DNA methylation patterns from non-invasive cheek swab samples. Its two main product lines — the Pet Age Test (one-time chronological age estimation, $120) and the HealthScore™ test (biological health scoring with disease-risk association, $250 single / subscription plans) — use proprietary methylation analysis to deliver pet-specific health insights and longevity tracking through a web-based portal.

Product overview

EpiPaws offers a portfolio of epigenetic testing products for dogs and cats centered on two main product lines: the HealthScore™ tests (for dogs and cats) which provide comprehensive wellness screening, biological age estimation, disease-risk association, and ongoing health tracking with subscription plans; and the Pet/Age Tests (for dogs, cats, and rescue pets) which provide one-time age estimation with health insights specific to the pet's life stage. All products use DNA methylation analysis from cheek swab samples to measure epigenetic markers linked to aging and health.

Differentiator

Problem solved

Functional benefit

Products and services

• HealthScore™ Test for Dogs

Quantifiable outcome

• Age estimation accuracy within 12 months of actual age for most samples; 75% of validation samples within 5 months of actual age
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Fit Pets for Rescues (FPR)minorGTM or Marketing Partner · 13 February 2026EpiPaws leverages the Healthy Pet Connect telemonitoring platform within the Fit Pets for Rescues Ideal Weight Challenge, a six-week veterinary-supervised weight management program for overweight pets. EpiPaws' technology connects home pet health data with veterinarians. Participation in the program is free for clinics, pet parents, veterinary student club members, and rescues.
• The Cat Health CompanycoreStrategic or Co-development Partner · 3 October 2024The Cat Health Company (Bucharest-based startup developing therapeutics to extend feline lifespan and healthspan) is collaborating with EpiPaws on a study involving 100 cats to understand genes involved in feline aging and develop new treatments. EpiPaws provides epigenetic testing and analysis services for the study.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Wisdom Panel (Mars Petcare): Wisdom Panel is the largest pet DNA testing brand, owned by Mars Petcare. Same DTC pet genetic-testing category as EpiPaws but at much greater scale and with broader retail/vet distribution; a logical acquirer or competitor for epigenetic expansion.

Emerging players

• Elysium Health: Elysium markets an epigenetic age test (Index) to consumers and conducts longevity research. Closely related as a science-led, DTC epigenetic-testing brand; useful comparison for credibility, pricing, and consumer education strategy.
• Tally Health: Tally Health sells a direct-to-consumer epigenetic age test for humans using DNA methylation analysis. The closest technology peer to EpiPaws — same DNAm core science — and a useful proxy for productization and consumer education of epigenetic tests.
• PetDx: PetDx is a molecular diagnostics company with a liquid biopsy test for canine cancer. Comparable in applying advanced molecular/DNA-based science to canine disease detection, though positioned as a clinical diagnostic rather than a DTC wellness product.

Direct peers

• Basepaws (Zoetis): Basepaws offers at-home DNA tests for cats (breed, health, oral microbiome) and was acquired by Zoetis. Closest direct comparable for EpiPaws' cat epigenetic product line, particularly for the still-unreleased Cat HealthScore.
• Orivet: Orivet provides pet DNA testing and personalized wellness plans for both dogs and cats, with a hybrid DTC + veterinary-channel model. Directly comparable in offering mix and target customer (pet parents and vets).
• Embark Veterinary: Embark sells direct-to-consumer DNA tests for dogs (breed, ancestry, health-risk screening) — directly comparable GTM motion, customer (US pet parents), and product category (genomic pet health insights), though Embark focuses on DNA rather than epigenetics.
• DNA My Dog: DNA My Dog sells lower-priced canine DNA tests (breed, predisposition) direct to consumers. Same e-commerce-only distribution and rescue-pet-age positioning as EpiPaws' Pet Age Test, though at lower price points.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/EpiPaws4Pets

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EpiPaws